Valiant Organics reports 39.60% yoy growth in revenue; stock trades lower

9 Feb 2022 , 02:33 PM

Valiant Organics Limited reported consolidated revenue of Rs288.40cr for Q3 FY’22 as against Rs206.60cr for Q3 FY’21, reporting growth of 39.60% yoy driven mainly by robust demand environment and contribution from new product additions like PAP and Para Anisidine.

Its total income for the 9M period ended December 2021 was reported at Rs805.60cr as against Rs520.80cr for the previous 9M period, gaining 54.70% yoy.

The company’s consolidated PBT stood at Rs43.70cr for December 2021 quarter, as against Rs47cr for the previous corresponding quarter, down by 7% yoy.

Its consolidated EBITDA for Q3 FY’22 was reported at Rs50.20cr against Rs51.70cr for Q3 FY’21, declining 2.9% yoy.

EBITDA for the 9M period ending December 2021 stood at Rs147.80cr against Rs146.90cr for the 9M period ending December 2020, marginally up by 0.6% yoy.

EBITDA margin settled at 18.35% for Q3 FY’22 against 28.21% for Q3 FY’21.

Its consolidated PAT for the quarter ended December 2021 stood at Rs32.20cr against Rs34.50cr for the quarter ended December 2020, a decline of 6.7% YoY. PAT for the 9M period ending December 2021 stood at Rs90.80cr against Rs96.40cr for the previous 9M period, declining 5.8% YoY.

Its PAT margin narrowed to 11.27% for Q3 FY’22 against 18.51% for Q3 FY’21 owing to elevated input costs and freight prices.

At around 2.33 PM, Valiant was trading at Rs1,105.60 against its previous closing price of Rs1,110.75, marginally down by Rs5.15 or 0.46%. It touched today’s high and low of Rs1,132.05 and Rs1,101 respectively.